Market Cap 14.09M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 63,000
Avg Vol 135,674
Day's Range N/A - N/A
Shares Out 4.93M
Stochastic %K 6%
Beta -2.43
Analysts Sell
Price Target $9.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
zambono
zambono Jan. 14 at 1:10 PM
$TPST why would anyone want to buy if either doom or dilution are the next steps? I am surprised its not under $1 already.
0 · Reply
saddy12345
saddy12345 Jan. 14 at 12:57 PM
$TPST CH 11 in the next days. Yey!
0 · Reply
Xamayca
Xamayca Jan. 14 at 12:12 PM
$TPST What TPST can do is scoop up all the panic sold shares and gain the upper hand in the vote that way. I’m pretty sure voted shares votes are invalidated once they are sold, actually not sure how that works
0 · Reply
frankPF
frankPF Jan. 14 at 11:20 AM
$TPST Zeit zu gehen und vervielfache bei 0.80 📌 Fazit ❗ Nein – die Aktionäre können den Deal realistisch nicht verhindern. Die Stimmen der Altaktionäre reichen nicht aus, weil: Factor durch die neuen Aktien die Mehrheit bekommt Das Board geschlossen dafür ist Die finanzielle Lage Tempest keine Alternative lässt Das ist ein klassischer „Reverse Merger / Rescue Deal“, bei dem die Altaktionäre faktisch nur noch zusehen können.
4 · Reply
Onedaytolive
Onedaytolive Jan. 14 at 8:57 AM
$TPST Factor is asserting unauthorized use of its patented technology. → Factor holds multiple U.S. patents (e.g., U.S. Patent Nos. 10,662,410, etc.) related to TALENs, a gene editing technology. This technology pertains to gene editing using synthetic mRNA. 🔹 Factor claims that Cellectis incorporated its TALEN technology without permission. → Factor alleges that its patented technology was misappropriated, specifically because the gene editing program was used in CAR-T and hematopoietic stem cell therapy research, and the results led to a joint development and licensing agreement between AstraZeneca and Cellectis. Specifically, the situation is as follows: • Factor claims it notified Cellectis of its intellectual property in 2013. • Despite this, Factor alleges Cellectis incorporated Factor's technology into its research program without obtaining a license.
2 · Reply
HectorNumba9
HectorNumba9 Jan. 14 at 7:55 AM
$TPST Soon start buying slowly again no rush
0 · Reply
Michl2000
Michl2000 Jan. 14 at 6:21 AM
$TPST AGM will be no great fun for everyone including Brady and board
0 · Reply
Michl2000
Michl2000 Jan. 14 at 6:13 AM
$TPST we are the unlucky rest here, that's still surprised about the fact that share price can still develop worse and worse. Quite obviously it can. The value of 1120 + 1495 seems to be very close to zero.
3 · Reply
Michl2000
Michl2000 Jan. 14 at 6:02 AM
$TPST i wonder how the other 13 or 14 offers looked like, if the Factor offer has been evaluated as the most interesting one 🤣🤣🤣
0 · Reply
Xamayca
Xamayca Jan. 14 at 12:09 AM
$TPST Tempest flea market
0 · Reply
Latest News on TPST
Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop


Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain


Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB


Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan


zambono
zambono Jan. 14 at 1:10 PM
$TPST why would anyone want to buy if either doom or dilution are the next steps? I am surprised its not under $1 already.
0 · Reply
saddy12345
saddy12345 Jan. 14 at 12:57 PM
$TPST CH 11 in the next days. Yey!
0 · Reply
Xamayca
Xamayca Jan. 14 at 12:12 PM
$TPST What TPST can do is scoop up all the panic sold shares and gain the upper hand in the vote that way. I’m pretty sure voted shares votes are invalidated once they are sold, actually not sure how that works
0 · Reply
frankPF
frankPF Jan. 14 at 11:20 AM
$TPST Zeit zu gehen und vervielfache bei 0.80 📌 Fazit ❗ Nein – die Aktionäre können den Deal realistisch nicht verhindern. Die Stimmen der Altaktionäre reichen nicht aus, weil: Factor durch die neuen Aktien die Mehrheit bekommt Das Board geschlossen dafür ist Die finanzielle Lage Tempest keine Alternative lässt Das ist ein klassischer „Reverse Merger / Rescue Deal“, bei dem die Altaktionäre faktisch nur noch zusehen können.
4 · Reply
Onedaytolive
Onedaytolive Jan. 14 at 8:57 AM
$TPST Factor is asserting unauthorized use of its patented technology. → Factor holds multiple U.S. patents (e.g., U.S. Patent Nos. 10,662,410, etc.) related to TALENs, a gene editing technology. This technology pertains to gene editing using synthetic mRNA. 🔹 Factor claims that Cellectis incorporated its TALEN technology without permission. → Factor alleges that its patented technology was misappropriated, specifically because the gene editing program was used in CAR-T and hematopoietic stem cell therapy research, and the results led to a joint development and licensing agreement between AstraZeneca and Cellectis. Specifically, the situation is as follows: • Factor claims it notified Cellectis of its intellectual property in 2013. • Despite this, Factor alleges Cellectis incorporated Factor's technology into its research program without obtaining a license.
2 · Reply
HectorNumba9
HectorNumba9 Jan. 14 at 7:55 AM
$TPST Soon start buying slowly again no rush
0 · Reply
Michl2000
Michl2000 Jan. 14 at 6:21 AM
$TPST AGM will be no great fun for everyone including Brady and board
0 · Reply
Michl2000
Michl2000 Jan. 14 at 6:13 AM
$TPST we are the unlucky rest here, that's still surprised about the fact that share price can still develop worse and worse. Quite obviously it can. The value of 1120 + 1495 seems to be very close to zero.
3 · Reply
Michl2000
Michl2000 Jan. 14 at 6:02 AM
$TPST i wonder how the other 13 or 14 offers looked like, if the Factor offer has been evaluated as the most interesting one 🤣🤣🤣
0 · Reply
Xamayca
Xamayca Jan. 14 at 12:09 AM
$TPST Tempest flea market
0 · Reply
ManiacalSlug
ManiacalSlug Jan. 13 at 11:21 PM
$TPST Yet another new all time low after hours! Maybe we would have been better hiring a crackhead off the street!?
3 · Reply
lgb2
lgb2 Jan. 13 at 11:10 PM
$TPST what a crock of shit
0 · Reply
JonDsoCal
JonDsoCal Jan. 13 at 11:09 PM
$TPST The only pleasure Tempest has given me in months was just now, casting 10000 “no” votes.
0 · Reply
lgb2
lgb2 Jan. 13 at 11:09 PM
$TPST guess we are dead rip
0 · Reply
holmesriley
holmesriley Jan. 13 at 11:08 PM
$TPST not a fan of the deal with the info given. Need to tell us about 2003 but I’m sure they can’t or won’t. Same with 1495. Haven’t voted yet but a no equals certain doom, no guarantee of a fire sale. Anything under 10$ is not acceptable. A yes mean dilution but we could get to mid 2027 with maybe something a no gets us to march 2026 then nothing. I can’t wait until 2027 but I can’t take 2$/ share either. Wish they would do a PR.
5 · Reply
joeyknowie
joeyknowie Jan. 13 at 10:34 PM
0 · Reply
claybridge
claybridge Jan. 13 at 9:12 PM
$TPST Brady you bastard SOB...
0 · Reply
Xamayca
Xamayca Jan. 13 at 9:06 PM
$TPST There goes Brady’s leverage no one wants the deal. I don’t want to lose money but watching his options go poof is def poetic justice
0 · Reply
ManiacalSlug
ManiacalSlug Jan. 13 at 8:55 PM
$TPST That’s maybe the tenth maybe the twentieth new all-time company history low that it’s hit since the Factor ‘funding’ was announced. No justification, no explanation, no support for the deal, no rational, no alternatives. It’s like the mafia forced this via black ail and gunpoint except Brady and Angel come out winners at everyone else’s expense. Sabby is the last hope here unless some unknown drops, they will likely manipulate pump it 2-3 days prior to the vote on 1/27 to cash out their warrants then dump it to a dollar. With $11 million cash bankruptcy liquidation is the best option here, even if their products are worth zero, at least we will find that out through that route.
1 · Reply
Xamayca
Xamayca Jan. 13 at 8:42 PM
$TPST B.P. Limbo?
0 · Reply
fantastex
fantastex Jan. 13 at 8:39 PM
$TPST still no volume. Its heading to 2.5 or 2. Sadly
1 · Reply
Michl2000
Michl2000 Jan. 13 at 8:17 PM
$TPST please no new technical analysis 🙏, had enough of this
0 · Reply